Compare Elanco Animal Health Incorporated Common Stock (ELAN) vs Novagold Resources Inc. (NG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elanco Animal Health Incorporated Common Stock vs Novagold Resources Inc. — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.65 (market cap $11.20B), while Novagold Resources Inc. trades at $6.37 (market cap $2.90B). The key difference: Elanco Animal Health Incorporated Common Stock is far larger — about 3.9× Novagold Resources Inc.'s market cap, and Elanco Animal Health Incorporated Common Stock is trading nearer its 52-week high, Novagold Resources Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Novagold Resources Inc. for 0 Days on average.
| ELAN | NG | |
|---|---|---|
Market Cap | $11.20B | $2.90B |
Volume | 3,345,224 | 3,973,464 |
Sector | Health | Basic Materials |
52-Week High | $26.84 | $14.20 |
52-Week Low | $19.80 | $5.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.58B | $2.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elanco Animal Health Incorporated Common Stock
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →
